Arrowhead Pharmaceuticals (ARWR) Analysts See $-0.13 EPS; Wesbanco Bank Lowered Alibaba Group Holding LTD (BABA) Stake By $2.81 Million

November 15, 2017 - By Ellis Scott

Analysts expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report $-0.13 EPS on December, 13.They anticipate $0.18 EPS change or 58.06% from last quarter’s $-0.31 EPS. After having $-0.07 EPS previously, Arrowhead Pharmaceuticals Inc’s analysts see 85.71% EPS growth. The stock decreased 1.39% or $0.05 during the last trading session, reaching $3.56. About shares traded. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has declined 67.27% since November 15, 2016 and is downtrending. It has underperformed by 83.97% the S&P500.

Wesbanco Bank Inc decreased Alibaba Group Holding Ltd (BABA) stake by 24.48% reported in 2017Q2 SEC filing. Wesbanco Bank Inc sold 20,092 shares as Alibaba Group Holding Ltd (BABA)’s stock rose 22.58%. The Wesbanco Bank Inc holds 61,973 shares with $8.73 million value, down from 82,065 last quarter. Alibaba Group Holding Ltd now has $465.59 billion valuation. The stock declined 0.98% or $1.79 reaching $180 per share. About 156,321 shares traded. Alibaba Group Holding Ltd (NYSE:BABA) has risen 57.33% since November 15, 2016 and is uptrending. It has outperformed by 40.63% the S&P500.

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. The company has market cap of $266.19 million. Using a portfolio of ribonucleic acid chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. It currently has negative earnings. The Firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins.

Among 6 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Arrowhead Research Corp had 16 analyst reports since August 5, 2015 according to SRatingsIntel. As per Monday, September 18, the company rating was upgraded by William Blair. The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) earned “Neutral” rating by PiperJaffray on Wednesday, November 30. The firm earned “Buy” rating on Thursday, November 10 by Chardan Capital Markets. On Wednesday, November 30 the stock rating was downgraded by Cantor Fitzgerald to “Hold”. As per Friday, September 25, the company rating was maintained by Piper Jaffray. On Wednesday, November 30 the stock rating was downgraded by Chardan Capital Markets to “Neutral”. The firm earned “Mkt Perform” rating on Wednesday, November 30 by William Blair. Cantor Fitzgerald initiated Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) rating on Friday, August 19. Cantor Fitzgerald has “Buy” rating and $15 target. The company was maintained on Monday, June 26 by Jefferies. Cantor Fitzgerald maintained the stock with “Hold” rating in Monday, September 25 report.

Wesbanco Bank Inc increased Salesforce.Cominc (NYSE:CRM) stake by 20,330 shares to 63,960 valued at $5.54 million in 2017Q2. It also upped Amazon.Com (NASDAQ:AMZN) stake by 493 shares and now owns 21,448 shares. Jp Morgan Chase (NYSE:JPM) was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :